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The recombinant canarypox vector, ALVAC-HIV, together with human immunodeficiency virus (HIV) gp120 envelope glyco-
protein, has protected 31.2% of Thai individuals fromHIV acquisition in the RV144 HIV vaccine trial. This outcome was unex-
pected, given the limited ability of the vaccine components to induce CD8 T-cell responses or broadly neutralizing antibodies.
We vaccinated macaques with an immunization regimen intended to mimic the RV144 trial and exposed them intrarectally to a
dose of the simian immunodeficiency virus SIVmac251 that transmits few virus variants, similar to HIV transmission to humans.
Vaccination induced anti-envelope antibodies in all vaccinees and CD4 and CD8 T-cell responses. Three of the 11 macaques
vaccinated with ALVAC-SIV/gp120 were protected from SIVmac251 acquisition, but the result was not significant. The remaining
vaccinees were infected and progressed to disease. The magnitudes of vaccine-induced SIVmac251-specific T-cell responses and
binding antibodies were not significantly different between protected and infected animals. However, sera from protected ani-
mals had higher avidity antibodies to gp120, recognized the variable envelope regions V1/V2, and reduced SIVmac251 infectivity
in cells that express high levels of47 integrins, suggesting a functional role of antibodies to V2. The current results emphasize
the utility of determining the titer of repeated mucosal challenge in the preclinical evaluation of HIV vaccines.
To date, there have been only four large-scale human immuno-deficiency virus (HIV) vaccine efficacy trials (1–4). Of these
four trials, only the RV144 trial, the largest HIV vaccine trial so far
concluded in humans, showed a limited but significant protection
(31.2%) from HIV acquisition (P  0.04) in the 16,395 partici-
pants (4, 5). This result has engendered cautious optimism about
the feasibility of a vaccine forHIV. The RV144 trial was conducted
in cohorts of Thai men and women primarily at risk for HIV
infection via heterosexual exposure. The vaccine regimen in-
cluded four inoculations of the recombinant avian poxvirus live
vector ALVAC-HIV (vCP1521), expressing the Gag-Pro of HIV
clade B; a membrane-anchored clade E gp120; and two simulta-
neous inoculations of the gp120 proteins AIDSVAX B/E, a biva-
lent recombinant gp120 of clades B and E. The result of the trial
was unexpected (6–8), in part because in two prior trials in Thai-
land and the United States, the AIDSVAX B/E or B/B vaccines
alone failed to protect from HIV acquisition (2, 3). The fourth
HIV vaccine efficacy study, the STEP trial, tested three inocula-
tions of an adenovirus 5-based vaccine (MRKAd5) containing
HIV gag, pol, and nef inserts in multicenter cohorts from North,
Central, and South America and Australia (1). Despite the ability
of the Ad5-based vaccine platform to elicit stronger T-cell re-
sponses than the combination of vCP1521 and AIDVAX, no pro-
tection against HIV acquisition was observed.
The mode of HIV transmission and HIV incidence differed
among these trials. Heterosexual exposure (female to male) was
the predominant mode of transmission in the RV144 cohort, and
the HIV incidence was less than one infection per 100 people
yearly. In contrast, HIV transmission occurred mostly by sexual
exposure amongmen who have sex withmen (MSM) in the STEP
trial and the AIDSVAX B/B trial and by needle sharing in the
AIDSVAXB/E trial (2, 3). TheHIV incidencewas between three to
four infections per 100 people yearly, in both the STEP and the
two AIDSVAX trials (1–3). Thus, whether the nature of the vac-
cine-elicited immune responses (9) and/or differences in the
mode or risk of exposure to HIV account for the differential out-
come in these trials remains unclear. The reported efficacy of vac-
cine modalities, similar to those used in the RV144 trial, varied in
different preclinical studies using animals of different ages and
viral challenges varying in identity, coreceptor usage, dose, and
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route (10–18). Recent evidence suggests that the dose of challenge
exposure to the CCR5-tropic simian immunodeficiency virus
SIVmac251 affects vaccine efficacy: at higher doses of challenge ex-
posure, multiple virus variants were transmitted and vaccine pro-
tection was diminished (19) (M. Vaccari, B. F. Keele, S. E. Bos-
inger, M. N. Doster, J. Zhong-Min Ma Pollara, A. Hryniewicz, G.
Ferrari, G. Yongjun, D.N. Forthal, D. Venzon, C. Fenizia, T.Mor-
gan, D. C. Montefiori, J. Lifson, C. Miller, G. Silvestri, M. Rosati,
B. K. Felber, G. Pavlakis, J. Tartaglia, G. Franchini, submitted for
publication). It is estimated that in humans, the risk of HIV trans-
mission by different exposures ranges between 1:10 and 1:1,000
per encounter (20–23). For most heterosexual transmissions,
when infection occurs, a single viral variant, or only few variants,
initiate systemic infection (24). Here, we explored the ability of
using titers in intrarectal challenge of Indian rhesus macaques
with SIVmac251 to model vaccine efficacy observed in humans by
using vaccines similar to those used in the AIDSVAX and the
RV144 trials and by using a dose of SIVmac251 intended to transmit
few viral variants (24).We found that, using these conditions, this
macaque model recapitulated the reported efficacy of this vaccine
in humans. As in humans, antibody (Ab) to the variable regionV2
of the envelope may be important for protection.
MATERIALS AND METHODS
Animals and study design. We used 34 colony-bred Indian rhesus ma-
caques (Macaca mulatta) obtained from Covance Research Products (Al-
ice, TX). The animals were housed andmaintained in accordancewith the
standards of the Association for the Assessment and Accreditation of Lab-
oratory Animal Care (AAALAC). All rhesus macaques were tested for
simian retrovirus, simian T-cell leukemia virus type 1, and herpesvirus B
before the study. The major histocompatibility typing for selected alleles
was performed as previously described (25) and is depicted in Table 1.
Macaques were immunized with ALVAC-SIV and gp120 in alum (11 an-
imals) or with gp120 in alum alone (12 animals). The remaining 11 ani-
mals received alum only as a control. Immunization with 108 PFU of
ALVAC-SIV Gag, Pol, and Env (16) was performed at 0, 4, 12, and 24
weeks by the intramuscular route in the thigh and the gp120 immuniza-
tion (200 mg of SIV-gp120 protein [26] formulated in alum) intramus-
cularly in the contralateral thigh, at weeks 12 and 24. The control group
received alum intramuscularly at weeks 12 and 24. All macaques were
exposed to a repeated dose of a 1:500 dilution of SIVmac251 (120 50% tissue
culture infective doses [TCID50] on cells) starting at week 28, as previ-
ously described (27).
Viral load quantification–single-genome amplification (SGA) anal-
ysis and tripartite motif-containing protein 5 alpha (TRIM5) geno-
typing. Plasma SIV RNA was quantified by nucleic acid sequence-based
amplification (NASBA), as previously described (28). SIVDNAwas quan-
tified in the blood and tissue of macaques by quantitative PCR, as previ-
ously described (29).
Transmitted/founder viruses and their progeny were identified by sin-
gle-genome amplification (SGA) of SIV RNA from plasma or rectal
pinches. SIV RNA was extracted, and limiting-dilution PCR of newly
synthesized cDNA was performed. Transmitted/founder virus lineages
were identified by low-diversity sequence and by single sequences with
unique mutations. Phylogenetic trees were generated using ClustalW.
The TRIM5 genotype was analyzed for all of the macaques included
in the study andwas previously described (30). Briefly, genomicDNAwas
isolated from peripheral bloodmononuclear cells (PBMCs), and the 526-
nucleotide PCRproduct of theB30.2/SPRYdomain of TRIM5was direct
sequenced. The sequences of the primers utilized both for PCR and for the
sequencing reaction were CAGTGCTGACTCCTTTGCTTG for the for-
ward primer and GCTTCCCTGATGTGATAC for the reverse primer.
The sequences were then aligned with the genomic DNA sequence of the
rhesus macaque (accession number DQ842021.1) to characterize the
polymorphisms at nucleic acid positions 997, 1,015 to 1020, and 1,022 of
TRIM5.
ELISpot assays. T-cell responses: the enzyme-linked immunosorbent
spot assays (ELISpot) were performed using monkey gamma interferon
(IFN-) ELISpot kits from Mabtech in triplicate on freshly isolated
PBMCs. A total of 3 105 cells/well was used with or without stimulation
with the SIVmac251 Gag or Env overlapping peptides as described previ-
ously (29). Concanavalin A (ConA; Sigma-Aldrich) was used as a positive
control (1 g/ml final concentrations). The cells were then incubated at
37°C in a 5% CO2 atmosphere for 24 h and washed. The plates were
assayed for IFN--producing cells as per the manufacturer’s protocol
(MABTECH ELISpot plus for the monkey IFN- kit). Spot-forming cells
(SFC)were counted on an ELISpot reader. The results are expressed as the
number of spots per 106 cells after subtracting the number of spots in
unstimulated wells.
B-cell responses. SIVEnv-specific or total IgGor IgA antibody-secret-
ing cells were analyzed by ELISpot as described previously (31). Briefly,
MultiScreen96-well plates (MilliporeMAIPS4510)were incubatedwith 70%
ethanol, rinsed four timeswith1phosphate-bufferedsaline (PBS), and then
coatedwith 500 ng/well of SIVmac251 gp120 (AdvancedBioScience Laborato-
ries, Inc.) in PBS or 10g/ml of goat anti monkey IgG or IgA (KPL). Coated
plateswere incubatedat4°Covernight.Plateswerewashed twicewith1PBS
and blocked with RPMI with 10% fetal bovine serum (FBS) and 3% bovine
serum albumin (BSA) for 2 h at 37°C. Peripheral blood mononuclear cells
TABLE 1 Mamu class I genotypes of macaques
Controls ALVAC-SIV/gp120 gp120
Animal no. Class I allele(s) Animal no. Class I allele(s) Animal no. Class I allele(s)
P065a A01/A08/B01/B17
P064a A01/A02 P062a A01/A02 P122 A08/B01
P146 A08 P063 A02 P123 A08/B01
P149 Negb P067 A02/A08/B01 P124 A02/A08
P158 A02/B03 P112a A01/A08 P126 A08
P161 A02 P147 Neg P127 A02/B01
P258 Neg P148 A08 P132 A08/B01
P262 B01 P150 B03/B08 P133 A08/B01
M381a A01 P172 B01 P135 A08
M385a A01/A08 P250 A08 P137 Neg
M895 B17 B017/B01/BO3/A02 P254 A02/B04 P139a A01/A08
M903 A02/A11/B03 M624a A01 M927a A01/B01
a MamuA01.
b Neg, animals negative for all major histocompatibility complex alleles tested: MamuA01, A02, A08, A11, B01, B03, B04, B08, B17.
Antibody Avidity and Protection from SIVmac251
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were stimulatedwith 1g/mlCpG(ODN-2006;Operon), 0.5g/mlCD40L,
and 50 ng/ml interleukin 21 (IL-21) (Peprotech) in complete medium for 3
days at 37°C in 24-well plates. Stimulated PBMCs were then harvested and
washed, and 3 105 cells were plated in 200l of RPMI containing 10%FBS
and incubated overnight at 37°C. Plates were then washed five times in PBS
with 0.05%Tween20 (Sigma) (PBS-T) and incubatedwith 100l of 1g/ml
of biotinylated goat anti-monkey IgGor IgA (Rockland) inPBS-T containing
1% FBS. Plates were then washed and incubated for 1 h with 5g/ml horse-
radish peroxidase (HRP)-avidin D conjugate (Vector Laboratories, CA) in
PBS-T and 1%FBS. Plates werewashed a total six timeswith PBS-T, the final
three washes were donewith PBS, and plates were developed using 3-amino-
9-ethyl-carbazole (AEC; Sigma). Spot quantitation was performed by using
an ELISpot reader.
Lymphocyte proliferation assays. Proliferation was performed using
as a readout [3H]thymidine incorporation as described elsewhere (29).
Briefly, fresh PBMCs were cultured at 105 cells/well in triplicate for 3 days
in the absence or the presence of native high-performance liquid chroma-
tography (HPLC)-purified SIVmac251 p27Gag and gp120 Env proteins
(Advanced BioScience Laboratories) or ConA as a positive control. The
cells were then pulsed overnight with 1 Ci of [3H]thymidine before
harvest. The stimulation indexwas calculated as the fold thymidine incor-
poration into cellular DNA over medium control.
As an alternative approach to measure lymphocyte proliferation, car-
boxyfluorescein succinimidyl ester (CFSE) staining was performed on
cryopreserved peripheral blood lymphocytes. These cells were incubated
with 5 mM CFSE (Invitrogen) in PBS for 5 min at room temperature
(RT), and cells werewashed twicewithRPMI containing 10%FBS and 1%
antibiotics (R10). Cells were enumerated, and 1  106 cells were plated
per ml of R10 in 24-well plates containing 5 g/ml of SIV Gag, Env, or
ConA used as a positive control or left unstimulated. Plates were incu-
bated for 5 days at 37°C, and cells were harvested and stained for 30min at
4°CwithCD3 (clone SP34-2), CD8 (cloneRPA-T8), CD4 (clone L200), or
CD95 (clone DX2), all from BD Biosciences, in addition to the live/dead
aqua dye to discriminate dead cells (Invitrogen). After staining, samples
were washed with PBS, fixed with 1% paraformaldehyde (PFA), and ac-
quired on an LSRII flow cytometer using FACS DIVA 6.0 software (BD
Biosciences). The results are expressed as the frequency of Gag- or Env-
specific memory (CD95) CD28 CD4 or CD8 T cells after back-
ground subtraction (% CFSE low unstimulated cells). Data analysis was
performedusing FlowJo software (TreeStar), and datawere graphed using
GraphPad Prism.
Bindingantibodyassayandpeptidemapping.Todetect anti-SIVmac251-
binding antibodies, serial dilutions of plasma were incubated with the
lysate of SIVmac251 spiked with native purified gp120 Env protein of
SIVmac251 bound to microtiter enzyme-linked immunosorbent assay
(ELISA) plates, as described previously (32). Endpoint titers were defined
as the reciprocal of the highest serum dilution that gave an optical absor-
bency at 450 nm at least two standard deviations greater than average
values obtained with negative-control serum. For peptide mapping, the
sera were diluted to 1:20 and added to plates coated with peptides encom-
passing the entire SIVK6W gp120 amino acid sequence (33).
Avidity assay. A format of previously described capture ELISA for
HIV-1 gp120 (34, 35), in which HIV-1 gp120 is captured through its C
terminus by goat antibody D7324, was adapted for detecting antibodies
against SIV gp120. Recombinant SIV gp120 protein made from codon-
optimized SIVmac239 gp120 fused to the C-terminal tag of HIV-1 gp120 is
used as the antigen for the capture ELISA to detect SIV Abs against a
conformational epitope.
Ab avidity is determined by parallel ELISA as previously described
(27). Brief, heat-inactivated plasma samples were serially diluted and ap-
plied to a 96-well-plate-captured SIVmac239 gp120 as described above in
parallel duplicates. After 1 h of incubation, the plate was washed and half
of the samples were treated with Tris-buffered saline (TBS), while the
paired samples were treated with 1.5 M sodium thiocyanate (NaSCN;
Sigma-Aldrich) for 10 min at room temperature. The plate was washed
and detected with goat anti-monkey IgG-detecting Ab (Fitzgerald). The
plate was then developed for optical density (OD) readout of Ab binding
as described in reference 34. The avidity index (%) was calculated by
taking the ratio of theNaSCN-treated plasma dilution giving anODof 0.5
to the TBS-treated plasma dilution giving anODof 0.5 andmultiplying by
100. The plasma of uninfected normal macaque served as the negative
control. A high-avidity macaque monoclonal antibody (MAb) of 3.11H
(36) was included on every plate as the standard.
Surface plasmon resonance. Surface plasmon resonance (SPR) mea-
surementswere conductedwith aBiacore T100 usingCM5 chips prepared
as described below. The immobilization wizard packaged within the T100
control software was used to immobilize 1 uM streptavidin in 20 mM
sodium acetate, pH 4.2 (10-min contact time), to each flow cell (7,000
response units [RU]). Biotinylated cyclic V2 peptides (Fig. 5E) were pre-
pared at 1 M in 20 mM Tris, pH 7.4, and injected manually until 4,000
RU of peptide was captured by the streptavidin-coated surface. Following
two 30-s injections of 50 mM HCl, 1 mM biotin in 20 mM Tris, pH 7.4,
was then injected twice (60-s contact time) over the reference and ana-
lyzed flow cells.
Plasma samples were heat inactivated (56°C, 45 min) and centrifuged
(5 min, 4°C, 14,500 rpm), and the supernatant was filtered prior to use.
The plasma was diluted 1:50 in Tris-buffered saline, pH 7.4, and passed
over the chip surface at 30 l/min for 3 min followed by a 5-min dissoci-
ation period. At the end of the 5-min period, a 20-g/ml solution of
affinity-purified gamma chain-specific goat anti-monkey IgG antibody
(Rockland Inc., Gilbertsville, PA) was passed over the flow cells for 2 min
at a flow rate of 10 l/min. After a 70-s dissociation period, the peptide
and reference surfaces were regenerated using a 30-s pulse of 50mMHCl,
a 30-s pulse of 100 mM EDTA in 20 mM Tris, pH 7.4, and another 30-s
pulse of 50mMHCl followed by a 1-min injection of Tris-buffered saline,
pH 7.4. Nonspecific binding was subtracted, and data analysis was per-
formed using the BIA evaluation 4.1 software. The reported response
units for the IgG-specific values are the difference between the average
value of a 5-s window taken 60 s after the end of the anti-IgG injection and
the average value of a 5-s window taken 10 s before the beginning of the
anti-IgG injection. The data (RU) are presented as dot plots for individual
plasma samples.
Standard neutralization assays. Neutralization was measured as a
reduction in luciferase reporter gene expression after a single round of
infection in either TZM-bl or 5.25.EGFP.Luc.M7 (M7-Luc) cells as de-
scribed previously (10, 37). TZM-bl cells were obtained from the NIH
AIDS Research and Reference Reagent Program, as contributed by John
Kappes andXiaoyunWu.M7-Luc cells were kindly provided byNathaniel
R. Landau. For the TZM-bl assay, 200 TCID50 of virus were incubated
with serial 3-fold dilutions of test sample in duplicate, in a total volume of
150 l for 1 h out of 18 h at 37°C, as indicated, in 96-well flat-bottom
culture plates. Freshly trypsinized cells (10,000 cells in 100 l of growth
medium containing 75 g/ml DEAE-dextran) were added to each well.
One set of control wells received cells and virus (virus control), and an-
other set received cells only (background control). After the 48-h incuba-
tion, 100 l of cells was transferred to 96-well black solid plates (Costar)
for measurements of luminescence using the Britelite luminescence re-
porter gene assay system (PerkinElmer Life Sciences). Neutralization ti-
ters are the dilution at which relative luminescence units (RLU) were
reduced by 50% compared to that in virus control wells after subtraction
of background RLUs.
M7-Luc cells were maintained in RPMI 1640 containing 12% heat-
inactivated fetal bovine serum, 50 g gentamicin/ml, 0.5 g puromycin/
ml, 300 g G418/ml, and 200 g hygromycin/ml to preserve CCR5 and
reporter gene plasmids. This is aCEMx174 cell clone thatwas produced by
retroviral vector transduction to express CCR5 (CD4 and CXCR4 are
expressed naturally) and transfection to contain Tat-responsive Luc and
green fluorescence protein (GFP) reporter genes. For neutralization as-
says, 500 TCID50 of virus were incubated with serial dilutions of serum
samples in triplicate, in a total volume of 150 l for 1 h at 37°C in 96-well
Pegu et al.
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flat-bottom culture plates. M7-Luc cells were suspended at a density of
5 105/ml in growth medium containing DEAE-dextran (10 g/ml) but
lacking puromycin, G418, and hygromycin. Cells (100 l) were added to
each well. One set of control wells received cells and virus (virus control),
and another set received cells only (background control). Assay plates
were incubated until approximately 10% of cells, in virus control wells,
were positive for GFP expression by fluorescence microscopy (approxi-
mately 3 days). At this time, a 100-l suspension of cells was transferred to
a 96-well black solid plate (Costar) formeasurements of luciferase activity
as described above. Neutralization titers are the serum dilution at which
the number of RLUs was reduced by 50% compared to virus control wells
after subtraction of background RLUs.
Assay stocks of molecularly cloned Env-pseudotyped viruses (SIVmac251
CS.41, SIVmac239 0.23, SIVmac251 WY:30) were prepared by transfection in
293T cells and were titrated in TZM-bl cells as described previously (38, 39).
Assay stocksofunclonedTCLA-SIVmac251 andSIVmac251CS/2002 letvinwere
produced in H9 and human PBMCs, respectively, and were titrated in M7-
Luc and TZM-bl cells, respectively.
ADCC assay. Antibody-dependent cell-mediated cytotoxicity (ADCC)
activity mediated by plasma samples was detected by the GranToxiLux
(GTL) procedure as previously described (40). Briefly, CEM.NKRCCR5
target cells (41) were coated with recombinant SIVmac251 gp120 (Ad-
vanced Bioscience Laboratories Inc., Kensington, MD) and labeled with a
fluorescent target-cell marker (TFL4; OncoImmunin, Inc., Gaithersburg,
MD) and a viability marker (NFL1; OncoImmunin, Inc.). Labeled target
cells were washed and plated at 1  104 viable cells/well. Cryopreserved
human PBMCs from an HIV-seronegative donor served as effectors and
were added to the assay wells at an effector/target ratio of 30:1. Fluoro-
genic granzyme B (GzB) substrate (OncoImmunin, Inc.) was added to
each well to a final concentration of 0.25. After incubation for 5 min at
RT, serially diluted serum/plasma samples (4-fold; starting at 1:100) were
added to the assay wells. The plates were incubated for 15 min at RT,
centrifuged for 1 min at 300  g, and incubated for 1 h at 37°C and 5%
CO2. The plates were thenwashed, and cells were resuspended in 200l of
PBS containing 1% FBS. A minimum of 2,500 events representing viable
target cells was acquired for each well using an LSRII flow cytometer (BD
Biosciences, San Jose, CA). Data analysis was performed using FlowJo
8.8.4 software (Tree Star Inc., Ashland, OR). The percentage of GzB activ-
itywasdefinedas thepercentageof cells positive forproteolytically activeGzB
out of the total viable target cell population. The final results are expressed
after subtracting the background, represented by the percentage of GzB ac-
tivity observed inwells containing effector and target T cells in the absence of
serum/plasma. The results were considered positive if the percentage of GzB
activity after background subtraction was8%.
Virus reduction assay in the presence or absence of retinoic acid.
PBMC was isolated from EDTA blood pooled from four naïve Indian
rhesus macaques by Ficoll-hypaque centrifugation and depleted of CD8
T cells by magnetic beads (Dynal). The enriched CD4 T cells were cul-
tured in vitro with tosyl-activated magnetic beads (Dynal) coated with
equal amounts of anti-CD3 (clone FN18: NIH nonhuman primate re-
agent resource) and anti-CD28 (BD Biosciences) and 50 U rIL2 for 5 days
in a CO2 incubator in the absence or presence of 10 nM all-trans retinoic
acid (RA). Activated cells were subsequently washed, examined for ex-
pression of both 47 and CCR5 by flow cytometry (FACS Calibur), and
used as targets in infection assays.
For infection (TCID50) assay, plasma or serum samples were heat
inactivated at 56°C for 30 min, filtered using a 0.22-m membrane, and
diluted 1:10 in 100 l of medium in a 96-well plate. SIVmac251 grown in
rhesus PBMC with a titer of 8.2  104 TCID50/ml was serially diluted
4-fold in 50 l medium and added to the diluted serum/plasma. After
incubation for 1 h at 37°C, 2  105 CD3/CD28-activated CD4 T-cell
enriched PBMCs were added to each well in 50 l medium, making the
final serum dilution 1:20. Wells were thoroughly washed after 120 h to
remove residual virus and then replenishedwith freshmedium.Cells were
cultured for an additional 5 days with occasional replenishing of fresh me-
dium. To score infection, 100l of culture mediumwas removed from each
well for quantitation of SIV p27 level using the SIV antigen micro-ELISA kit
(ABL). TCID50 values were calculated using Spearman-Karber calculations.
Mucosal antibodies. Mucosal IgG and IgA binding antibodies were
measured by binding antibody multiplex assay as previously described
(42, 43) and SPR as previously described (44). Antibodies were eluted
from rectal Weck-cel in cold elution buffer (1 protease inhibitor cock-
tail [Calbiochem], 0.25%BSA) by spinning 2 times at 16,000 g for 15 to
20 min at 4°C. Total and SIV-specific immunoglobulin levels were mea-
sured by ELISA according to the manufacturer’s instructions (monkey
IgG ELISA,monkey IgA ELISA; AlphaDiagnostics, San Antonio, TX) and
expressed asg/ml to calculate specific activity for the binding responses.
The SIV antigens utilized in both the multiplex binding antibody assay
and SPR assay are SIVmac239 p55 Gag (Protein Sciences), SIV p27 Gag
(ImmunoDiagnostics, Woburn, MA), rgp41 (Immunodiagnostics),
SIVmac251 rgp130 (ImmunoDiagnostics, Woburn, MA), and SIV gp140
(provided by Bing Chen, Harvard). For analysis of SIV-specific IgG by
multiplex binding antibody assay, SIV proteins were coupled to micro-
spheres (Bio-Rad) and incubated with serial dilutions of samples, and
specific antibody binding was detected by biotinylated anti-monkey IgG
(Rockland) by mean fluorescent intensity (with background and blank
bead subtracted). Positive and negativemonkey serum controls were used
in each assay, and themidpoint titer (EC50) of each sample was calculated
using a four-parameter logistic fit (4-PL). The avidity of antibody binding
was measured on a BIAcore 4000 instrument (BIAcore/GE Healthcare)
using the multiplex array format (1 by 16) in which samples were flowed
over duplicate spots of 8 different antigen surfaces on a series S CM5 chip
(BIAcore/GE Healthcare). Proteins (pFB SIV gp140 and recombinant
gp130 SIV Mac 251) were immobilized to about 5 to 10,000 RU, and
peptideswere immobilized to about 1 to 3,000RU. The following peptides
were also used in this study: SIVmac251 V2 linear, SIVmac251 V2 S-S, cyclic
DLV SIVmac251, SIVmac251 LDV gp41, cyclic LDV. There were 7 animals
with both rectal and vaginal samples and 27 rectal samples included in this
study. Antigen surface activity was monitored using DBM5 IgG, HIVIG,
and serum samples as positive controls and Synagis MAb as the negative
control. DBM5 IgG was titrated (0 to 100 g/ml) to generate a standard
curve for calculating Weck sample IgG concentration. All Weck-cel ex-
traction samples were run undiluted and injected over each of the flow
cells with replicate spots (2) at 10 l/min for an association time of 120
s and a dissociation time of 450 s. Following each binding cycle, surfaces
were regenerated with a short injection (20 s) of glycine, pH 2.0. Each
surface activity was monitored by including DBM5 IgG (100 g/ml) in-
jection at regular interval of every 20 cycles. Bulk effect from a buffer
injection was subtracted from each IgG sample binding data. Data analy-
ses were performed with BIAevaluation 4000 and BIAevaluation 4.1 soft-
ware (BIAcore/GEHealthcare). Kinetic binding responses weremeasured
by averaging postinjection response units (RU) over a 10-s window and
dissociation rate constant, Kd(s	1), was measured during the postinjec-
tion/buffer wash phase (after the first 30 s to allow stabilization of signal)
following curve fitting to a Langmuir dissociation equation. A relative
avidity binding score was calculated for each IgG sample as follows: RU.s
(RU)/Kd(s	 1), where RU.s is the avidity score and (RU)/Kd(s	 1) is the
binding response. Higher levels of binding responses and a lower Kd are
indicators of higher-affinity interactions. For normalized responses,
binding responses of aDBM5 IgG titration at known concentrations on an
anti-monkey IgG chip surfacewere plotted to generate a calibration curve.
Equivalent IgG concentrations for each Weck sample were calculated us-
ing the slope of the standard curve. Weck samples with binding responses
above the highest DBM5 concentration of 100g/mlwere reported as 150
g/ml. Kinetic binding responses were normalized according to calcu-
lated concentrations.
Statistics. Differences between groups were assessed using the exact
Wilcoxon rank sum test, with P values corrected by theHochbergmethod
for multiple antigens tested and multiple pairwise group comparisons.
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Nucleotide sequence accession numbers. All 1,116 envelope se-
quences were deposited in GenBank under accession numbers JX497793
to JX498908.
RESULTS
Relative vaccine efficacy following mucosal exposure to a dose
of SIVmac251 that transmits few virus variants.We immunized 11
adult Indian rhesusmacaques, in a primeboost regimen,with four
intramuscular immunizations of the ALVAC-SIV recombinant
virus expressing the SIVK6W gag, pol, and env genes (15) and with
two coimmunizations with the SIVgp120 protein alum adju-
vanted. A second group of 12 macaques were immunized with
gp120 protein adjuvanted in alum and a third group of 11 animals
with the alum adjuvant alone (Fig. 1A). Animal groups were ran-
domized for the presence of protective class I alleles (Table 1). At
the end of the immunization regimen, all animals were exposed
FIG 1 Mucosal challenge exposure of macaques to low repeated doses of SIVmac251 dose. (A) Schematic representation of the study design. Four weeks after last
immunization (week 28), macaques were exposed to a total of five repeated doses of SIVmac251 (120 TCID50 each) given weekly by the intrarectal route. (B) The
rate of infection in the three groups is depicted; ALVAC-SIV/gp120, solid black line; gp120, dark dotted line; and control, light dotted line. SIV RNA levels in
plasmaof control (C), gp120-immunized (D), andALVAC-SIV/gp120-immunized (E) animals. The animals that remained uninfected in theALVAC-SIV/gp120
(M624, P250, and P148) group and the one in the gp120 group (M927) are boxed. (F) Geometric mean SIV RNA levels 
 standard error in plasma of
ALVAC-SIV/gp120 (triangle), gp120 (square), and control (circle) animals. (G) Viral DNA copies in rectal biopsy specimens collected at day 19 after infection
or after the fifth exposure to a low dose of SIVmac251 in the animals that remained uninfected (open symbols). (H)Mean percentage of change in blood CD4
 T
cell number following SIVmac251 infection. The uninfected animals are excluded from the analysis. Number of virus variants transmitted in control (I),
gp120-immunized (J), and ALVAC-SIV/gp120-immunized (K) macaques.
Pegu et al.
1712 jvi.asm.org Journal of Virology
 
weekly by the intrarectal route at a dose of 120 TCID50 of
SIVmac251, shown previously to result in transmission of only a
few virus variants (27). Infected animals were not rechallenged
once viremia was detected, and new challenges with SIVmac251
were terminated when all 11 animals in the control group became
viremic (five exposures). The choice to terminate the challenge
was supported by the notion that further challenges would not
have added significance to vaccine efficacy. We observed no sig-
nificant differences in the time of acquisition of SIVmac251 in the
three groups of animals (Fig. 1B). However, while all control an-
imals became infected (Fig. 1C), three (P148, P250, andM624) of
the 11macaques immunizedwith theALVAC-SIV/gp120 (27.3%)
and one (M927) of the 12 macaques immunized with gp120
(8.3%) remained uninfected (Fig. 1D and 1E). There were no sig-
nificant differences in viral loads between vaccinated animals and
controls; however, the ALVAC-SIV-vaccinated group demon-
strated transiently lower viremia in the acute phase than the con-
trol animals (Fig. 1F). Similarly, we observed no significant differ-
ence in the levels of SIV DNA in the rectum of vaccinated animals
and controls 3 weeks postinfection (Fig. 1G). SIVDNAwas unde-
tectable in the rectal mucosa collected at 3 weeks from the last
exposure of uninfected animals P148, P250, M624, and M927
(Fig. 1G). We observed no significant differences in CD4 T-cell
loss between infected vaccinated and control groups (Fig. 1H).
Although the viral SIVmac251 stock at the 120 TCID50 dose used for
challenge was previously shown to transmit few virus variants
(27), to assess the number of viral variants that established sys-
temic infections, we performed single-genome amplification
(SGA) and direct sequencing of the env gene to enumerate the
number of transmitted/founder variants. Unique transmitted lin-
eages were identified by phylogenetic analysis within the context
of the inoculum sequences, as described elsewhere (19). Control
and animals vaccinated with the combination of ALVAC-SIV and
gp120 had a median number of one variant, whereas the animals
immunized with gp120 alone had a median number of three vari-
ants (Fig. 1I to K). The difference in the number of transmitted
variants did not differ significantly among the groups. Since the
number of transmitted variants was greater in the gp120 group
and animals infected after the first or second challenge appeared to
havemore transmitted viral variants, we evaluated a potential cor-
relation between the number of transmitted variants and the
number of challenges. We found an inverse correlation between
the number of transmitted variants and the time of acquisition
when we analyzed all the animals in the study (R  	0.70, P 
0.0001). When this analysis was performed separately among the
two vaccine groups and the controls, the inverse correlation re-
mained significant for both the vaccinated groups (ALVAC-SIV/
gp120, R	0.84, P 0.0025; gp120, R	0.65, P 0.028) but
not the control group (R	0.31, P 0.42).
Vaccine-elicited T-cell responses. The immunogenicities of
the two vaccine regimens were assessed by comparing T cell re-
sponses prechallenge (week 27, 3 weeks after the last immuniza-
tion) to unvaccinated controls (Fig. 2). IFN-, measured by
ELISpot using PBMCs stimulated with SIV Gag and Env overlap-
ping peptides, demonstrated nonsignificant differences between
control and gp120-immunizedmacaques (P 0.071 for each) but
were significantly different for both antigens between ALVAC-
SIV/gp120-immunized animals and control (P 0.0069 and P
FIG 2 Vaccine-induced T-cell responses. All the data were obtained from PBMCs harvested at 3 weeks after the last immunization (week 27). All the data from
animals protected from SIVmac251 acquisition are depicted with open symbols. IFN--secreting cells measured by ELISpot in response to SIV Env (A) or Gag (B).
Results are shown as the number of spots per 106 cells, and each symbol represents one animal. Lymphoproliferative responses (LPR) measured by thymidine
incorporation to SIV Env (C) or Gag (D). The horizontal bars in the figures represent the average and standard error for the vaccinated and control animals.
Gating strategy for CD4 and CD8 CFSE memory (CD95) T cells (E). (F to I) Percentage of CD95 CFSE dim or negative CD8 or CD4 T cells that
proliferate following Env or Gag stimulation.
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0.0001, respectively) (Fig. 2A and B). Macaques immunized with
the ALVAC-SIV/gp120 developed significantly higher IFN-
ELISpot responses to Gag and Env than macaques immunized
with gp120 protein alone (P 0.011 and P 0.016, respectively)
(Fig. 2A and B). Lymphocyte-proliferative responses were mea-
sured by thymidine incorporation (Fig. 2C and D) or CFSE stain-
ing (Fig. 2E to I) following in vitro stimulation with SIV Gag- and
Env-purified proteins. Proliferation measured by thymidine in-
corporation showed a significant increase of stimulation indexes
in ALVAC-SIV/gp120 compared to gp120 or control groups after
Env (P 0.043 and P 0.0001) or Gag stimulations (P 0.035
and P 0.0009) (Fig. 2C andD). However, when the proliferative
ability of CD4 and CD8 T cells were measured with CFSE on
cryopreserved PBMCs, the differences between the two vaccinated
groups only approached statistical significance (Fig. 2E to I).
Vaccine-elicited B-cell responses. The envelope-specific
B-cell response was measured at week 27, 3 weeks after the last
immunization, by B-cell ELISpot, binding titers in blood, specific
activity in mucosal secretions, avidity of binding antibodies to
gp120, and the ability of antibodies to mediate ADCC. There was
a trend for a higher IgG to SIV gp120 in animals immunized with
ALVAC-SIV/gp120 than in control animals (P  0.072), and no
significant difference between the gp120-immunized and control
macaques (Fig. 3A). The mean binding antibody titers to the
gp120 envelope protein detected by ELISA in the sera were higher
in theALVAC-SIV/gp120 than in the gp120 group (P 0.018, Fig.
3B), but the levels of gp140 IgG-specific activity, measured in rec-
tal secretions, were not significantly different (Fig. 3C). The avid-
ity of antibodies to gp120 did not differ significantly in the two
immunized groups but was high in all the animals that were pro-
tected from infection (depicted as open symbols in Fig. 3D). The
avidity of mucosal IgG was tested by surface plasmon resonance
(44) against gp120 proteins or the V2 peptides, depicted in Fig.
S1A in the supplemental material, and did not differ significantly
in the two vaccinated groups (see Fig. S1A and B). The neutraliz-
ing titers in the M7-Luc assay were significantly higher in the
ALVAC-SIV/gp120 group than in controls and in gp120-vacci-
nated animals (P 0.0005 and P 0.0001) (Fig. 3E), whereas the
mean titers of neutralizing antibodies in the TZM-bl cell assay did
not differ between the two immunized groups (Fig. 3F). ADCC
was measured by calculating the maximum granzyme activity,
which was not significantly different in the two vaccinated groups
(Fig. 3G), andADCC titers, whichwere higher in theALVAC-SIV/
gp120 group (P 0.028, Fig. 3H).
Vaccine-elicited T- and B-cell responses in protection from
SIVmac251 acquisition or plasma virus level.We investigated the
immune responses that contributed to protection, delayed
SIVmac251 acquisition, or decreased plasma virus levels by analyz-
ing the vaccine-induced immune responses at week 27, 3 weeks
after the last immunization and 1 week prior to challenge expo-
sure to SIVmac251. T-cell responses to the Gag and envelope anti-
gens measured by IFN- ELISpot or proliferation assays did not
correlatewith time of acquisition or blood virus levels. Neither did
the number of IgG-producing B cells to envelope measured by
ELISpot nor envelope binding antibodies in blood or mucosal
secretions correlate with SIVmac251 acquisition. The only trend of
note was in the binding antibody titers to gp120, which were ap-
parently inversely correlated with the virus levels at week 3 (R 
	0.65, P  0.036, not corrected for multiple comparisons). No
correlation was found with prechallenge neutralizing antibody ti-
ters to SIVmac251 in both the M7-luc and the TZM-bl assays or
ADCC, using maximum granzyme levels, ADCC titers, avidity
and time of acquisition, or blood virus levels. However, the anti-
body in the sera of the four immunized, uninfectedmacaques had
significantly higher antibody avidity to gp120 than those from
macaques that became infected (P  0.012) (Fig. 4A). The anti-
body avidity to gp120 remained significantly higher over time
(3 and 6 weeks postchallenge) in the uninfected animals (P 
0.0018 and P  0.0060, respectively) than SIV-infected animals
(Fig. 4B and C). Interestingly, the significant difference in avidity
of antibodies to gp120 among uninfected or infected macaques
was not observed when the sera of these animals were tested
FIG 3 Vaccine-induced B-cell responses. All data presented in the figure were obtained from sera collected at week 27, 3 weeks after the last immunization. In
all the figures, the animals protected from SIV acquisition are depicted with open symbols, and the horizontal bars in the figures represent the average values and
standard errors. (A) Percentages of gp120-specific IgG of the total cell-producing IgG at week 27. (B) Endpoint titers of SIV Env-specific IgG in serum of animals
vaccinated with ALVAC-SIV/gp120, SIV gp120, or controls. (C) Gp140 IgG-specific activity in rectal secretions from vaccinated animals and controls. (D)
Avidity of antibodies to the SIVmac239 Env protein in sera of the animals vaccinated with either ALVAC-SIV/gp120 or SIV gp120 or controls. SIV-specific
neutralization activity measured in animal sera using SIV pseudotyped lentiviruses and either the M7-luc cell line (E) or TZM-bl cells (F) as targets. ADCC
capacity of antibodies in serum of all animals represented as the percent maximum granzyme activity (G) or serum ADCC titer (H).
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against a gp120 deleted in the V1 and V2 regions (Fig. 4D), sug-
gesting that antibody responses to the V1 and V2 regions of gp120
might be of importance.
Protection from HIV acquisition, in the RV144 human trial
(4), correlated significantly with the presence of antibody re-
sponse to V1/V2 (45). Since the data presented in Fig. 4A to D
suggested that immune responses to V1/V2 are also induced by
this vaccine regimen in macaques, we mapped the antibody re-
sponse induced by our vaccines. The sera of allmacaques collected
at week 27 were tested for their ability to recognize 89 linear over-
lapping peptides (15-mers), derived from the SIVK6W gp120 and
the gp41 (peptide 90 to 141) envelope amino acid sequence (33)
included in the ALVAC SIVgpe vaccine. Most of the macaques in
both vaccinated groups recognized linear V1 peptides 13 to 23
(Fig. 5A and B); some recognized the V2 peptides 23 to 32 (Fig. 5C
and D) and V3 peptides 50 to 55 (data not shown). Antibodies
directed to the V2 region encompassed between peptides 26 and
32 were significantly higher in infected ALVACgp120-vaccinated
animals than in infected gp120 vaccinees (P  0.031). However,
we did not observe a specific pattern of linear peptide recognition
to V2 using this approach (Fig. 5C and D; see also Fig. S1C in the
supplementalmaterial). Next, we evaluated serum recognition us-
ing the cV2a cyclic peptide that encompasses the entire amino acid
sequence of the SIVSME660, as well as the cV2c peptide, that has a
truncation of the first 17 amino acids of V2 (Fig. 5E). Both pep-
tides were tested in a surface plasmon resonance assay. Surface
FIG 4 Avidity of antibodies to gp120 and protection from SIVmac251 acquisi-
tion. Avidity index of antibody to the entire SIVmac239 gp120 in vaccinated
animals that were protected or SIV infectedmeasured at week 27, 3 weeks after
the last vaccination (A) or at three (B) or six (C) weeks after SIV infection. (D)
Avidity of antibody to the gp120 protein deleted in the V1 and V2 regions, in
protected and infected animals.
FIG 5 Evaluation of antibody responses targeting the V1/V2 loops of gp120. Serum antibody binding to peptides spanning the V1 region, amino acids 13 to 23
of the SIVmac251K6W gp120, in animals vaccinated with ALVAC-SIV/gp120 (A) or gp120 (B). Peptide binding is represented as average absorbance, and
uninfected animals are on the left in white bars. Binding to peptides spanning the V2 region, amino acids 26 to 32 of gp120, in the serum of ALVAC-SIV/gp120-
vaccinated (C) or gp120-vaccinated (D) animals. (E) The amino acid sequence (in single-letter amino acid code) of the linear V2 region of SIVmac239 and
SIVSME543.3, is presented in comparison to the SIVmacK6W sequence used in the ALVAC-SIV construct (33). Dots represent identical amino acid sequence. The
asterisk signifies one amino acid deletion. Each line represents a peptide whose number is depicted on the left. (F) Surface plasmon resonance with sera (week 27)
from uninfected and infected macaques assayed against the cV2c-truncated peptide. (G) Surface expression of 47 and CCR5 on CD4 T cells untreated (line
with squares) or treatedwith retinoic acid (RA; solid line). Reduction of SIVmac251 infectivitymediated by the sera of animals immunizedwithALVAC-SIV/gp120
and gp120 in RA-treated (H) or untreated (I) animals. (H and I) The log-transformed change in TCID50 pre- and postvaccination is shown with uninfected
animals in open symbols and infected animals in closed.
Antibody Avidity and Protection from SIVmac251
February 2013 Volume 87 Number 3 jvi.asm.org 1715
 
 
plasmon resonance demonstrated that the sera, collected at week
27 from the uninfected animals, had higher activity than those
that become infected, but this difference approached statistical
significance only when the cyclic cv2c-truncated peptide was used
in the assay and was based mainly on the result of one single
animal (Fig. 5F). The cV2c peptide is 75% identical to the V2
region of the SIVK6W envelope gene inserted in the ALVAC back-
bone used in this study. Importantly, the reactivity to the cV2c
peptide was also found in the assay in the mucosal samples of two
of the four protected macaques (data not shown).
The sera of ALVAC/SIV/gp120-immunized macaque reduce
SIVmac251 infectivity in vitro. Since our data suggested that the
antibody response and in particular the responses to the V1/V2
loop of the gp120 was higher in the ALVAC-SIV/gp120 group, we
developed a functional assay to investigate the ability of sera of the
immunized macaque to inhibit SIVmac251 infection in vitro.
The V2 has been shown to interact with the integrin 47 that
is expressed on the surface of activated CD4 T cells (37). Even
though blocking 47 does not inhibit infection, overexpression
of47 has been demonstrated to increase viral infectivity in stan-
dard infectivity assays, possibly by favoring clustering of CD4 and
CCR5 on the cell surface (46). We tested whether the preimmune
and immune sera of vaccinated macaques decreased SIVmac251 in-
fection in cells, whereby47 expressionwas enhanced by retinoic
acid (RA) treatment. Activated (CD8-T-cell-depleted) PBMCs,
cultured in the presence of RA, had an upregulation of 47 ex-
pression but similar levels of CCR5 expression (Fig. 5G). Sera
from animals before and after vaccination were mixed with serial
dilutions of SIVmac251, added to activated cells, and cultured for 10
days. TCID50 titers were then measured as the amount of virus
necessary to infect 50% of the cells in the presence of sera. Inter-
estingly, sera from ALVAC/SIVgp120 animals reduced SIVmac251
infectivity better in RA-treated cells than the sera of gp120-vacci-
nated animals (P 0.0027) (Fig. 5H). This trend was also seen in
cells not treated with RA, but the difference did not reach statisti-
cal significance (P 0.13) (Fig. 5I). The sera of the gp120-immu-
nized macaques did not affect SIVmac251 infectivity in RA-treated
or untreated cells (Fig. 5H and I).
DISCUSSION
A validated animal model could hasten progress in the develop-
ment of an effective vaccine for HIV. Here, we demonstrate, in a
small pilot study, that immunizations of macaques with vaccines
similar to those used in the HIV vaccine RV144 trial in Thailand,
which resulted in protection of one-third of the vaccinees from
HIV acquisition (4), also protected few vaccinatedmacaques from
acquisition of the highly pathogenic SIVmac251 using a dose of
challenge virus that transmits few virus variants (24). However,
because the macaque study was not powered sufficiently for scor-
ing protection, further studies will be needed to properly investi-
gate the correlates of protection. Restrictive TRIM5 alleles for
SIVmac251 replication did not account for the lack of SIVmac251
acquisition inmacaques P148, P250,M624, andM927, as demon-
strated in previously published work with this virus stock (30).
Interestingly, of the four vaccinated animals that resisted five chal-
lenge exposures, two carried the MamuA01 protective allele (an-
imals M624 and M927) (Table 1). However, because the control
group also had animals that carried the same protective allele (Ta-
ble 1) and nevertheless acquired SIVmac251 following mucosal
challenge, it is likely that vaccination, in combination with the
genotypic status, contributed to the protection from infection, as
also observed earlier with these vaccine modalities (15). In the
same conditions, vaccination with gp120 alone did not protect
from infection, except a single animal that carried the protective
MamuA01 allele and was also able to mount high titers of gp120
antibody with high avidity (Fig. 4A). Similar to humans vacci-
nated with an equivalent vaccine regimen (4), ALVAC-SIV/gp120
immunization did not protectmacaques fromCD4T-cell loss or
high virus plasma levels over time. The ALVAC-SIV/gp120 vac-
cines inmacaques elicited limitedCD4T-cell responses and neg-
ligible CD8 T-cell responses, as in humans (4). Similarly, all the
vaccinated macaques developed binding antibodies to the enve-
lope protein (4) and neutralizing antibodies to lab-adapted
SIVmac251. Because the study was not powered to assess correlates
of protection, we considered the results that follow as exploratory.
Vaccine-induced protection from SIVmac251 acquisition was sig-
nificantly associatedwith antibodywith high avidity for gp120 but
not with neutralizing activity in vitro, ADCC, or T-cell responses
measured by ELISpot, intracellular cytokine staining, and T-cell
proliferation. Interestingly, the significant difference in antibody
avidity to gp120 was lost when the gp120 protein, used in the
assay, had a deletion in V1 and V2. These data suggest that either
the V1/V2 could be among target epitopes of antibodies with high
avidity or that the V1 and/or V2may be necessary to maintain the
appropriate conformation of the gp120 protein for the optimal
binding of high-avidity antibodies, directed to regions other than
V1/V2. The results obtainedwith the cyclic cV2c peptide (Fig. 5F),
although only approaching statistical significance, suggest that V2
may be a target of high-avidity antibodies. In addition, our find-
ings with the virus reduction assay, following retinoic acid stimu-
lation of primary CD4 cells, suggest that the ALVAC-SIV prim-
ing may be important for the elicitation of antibodies able to
reduce viral infectivity under conditions whereby 47 is in-
creased by retinoic acid since the sera from animals immunized
with gp120 alone did not have this activity (Fig. 5H and I).
Studies by others also have found that antibody avidity to the
envelope was associated with reduced viral load following SHIV
and SIV challenge exposure (47), and conversely in another sys-
tem, low antibody avidity has been associatedwith poor protective
efficacy with an RSV vaccine (48).
The similarity of the results obtained in macaques here with
those reported in humans using equivalent vaccines, as well as in
those by others using different vaccine modalities (49, 50), is en-
couraging but needs to be confirmed by properly powered studies
since the present study confirms the usefulness of this macaque
model despite differences in the immunogens used. The ALVAC-
HIV vaccine used in humans expressed the gag-pro genes, whereas
the ALVAC-SIV vaccine used in the present study expressed the
gag-pol genes. The ALVAC-HIV in humans expressed a fusedHIV
clade E gp120 to the gp41 transmembrane domain of the HIVLAI
strain, whereas the ALVAC-SIV expressed the entire envelope
protein. The envelope protein boost in humans consisted of two
proteins: HIV clade E and clade B fused to the gD HSV signal
peptide and were produced in CHO cells (4). In macaques, we
used only the native monomeric SIVmac251 gp120 produced in T
cells. In addition, the challenge used in the macaque study here
was homologous (approximately 1% diversity in the envelope
gene of the challenge and the vaccine strain), whereas the vac-
cinated volunteers in the RV144 trial were likely exposed to
more genetically diverse clade E and AE strains (4). Hopefully,
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SIVmac251-based vaccines, constructed as the human vaccines,
may be proven, in properly powered animal studies, to confer
significant protection from SIVmac251 as observed within 3
years from vaccination in the Thai volunteers (4). Animal
models have accelerated the development of effective vaccines
for human diseases and significantly facilitated the identifica-
tion of correlates of protection (51–55), but the models should
reflect conditions of the human infection and disease as accu-
rately as possible (56). Notably, in the present study, the low
repeated doses of SIVmac251 used to challenge the macaques
resulted in the transmission of few virus variants, as typically
seen in heterosexual transmission of HIV-1 to humans. How-
ever, we noticed a significant correlation between time of ac-
quisition and number of variants transmitted in vaccinated but
not control animals, suggesting that in animals that are not
protected from infection, vaccination may be associated with
early transmission of a higher number of virus variants. Fur-
ther studies will be necessary to confirm these results. Our data
demonstrate that the low repeated dose challenge of rhesus
macaques with SIVmac251 may be a relevant model for poten-
tially defining correlates of protection, for demonstrating the
effectiveness of other candidate vaccines, and ultimately for the
improvement and optimization of vaccines against HIV.
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Supplementary Figure 1:  Sequence of the peptide used in the Resonance Plasmon assay on mucosal secretions. (A). Avidity IgG to the gp140 and 
gp130 Envelope proteins of SIVmac251, to the SIVmac251 mucosal (B) V2-linear, DLV, V2 S-S peptides, cyclic DLV, LDV and cyclic LDV SIVmac251 peptides. (B). 
Avidity of mucosal IgG to the same peptide used in B in uninfected and SIV-infected macaques (C).
